FOR IMMEDIATE RELEASE– June 4, 2021
CPR Therapeutics, Inc., a medical device start-up developing the first clinically effective, advanced, integrated systems for cardiopulmonary resuscitation (CPR), today announced that it has entered into a partnership with Design Catapult, Inc. to develop the CPR-T CathLab Optimized CPR System™ for in-hospital resuscitation of patients suffering cardiac arrest.
Design Catapult is a leading product development firm known for its creative edge in industrial design, mechanical and electrical engineering, software development, prototyping and production. It is one of the only engineering companies with experience in designing pneumatic CPR systems.
Norman Paradis MD, CPR Therapeutics’ Founder and CEO stated: “Cardiac arrest in the catheterization lab is a major clinical challenge. It is associated with dramatically worse patient outcomes. The standard response is manual CPR, which presents a number of challenges. Among these is that manual CPR requires cathlab staff does chest compressions directly in the x-ray beam. More importantly, data suggest that manual CPR is more injurious to the patient and less effective than our Vest-CPR. The CPR-T CathLab Optimized System TM is being developed to produce significantly better blood flows, while protecting cathlab personnel and causing fewer fractures of the chest. This is especially important in patients who might be anticoagulated.”
“Our partnership with Design Catapult is an important milestone for the company. Design Catapult has an extraordinary track record of rapidly and successfully developing world-class devices for major medical device companies. ”
Sam Iravantchi, Founder and President of Design Catapult, is also enthusiastic about this new partnership. “The CPR Therapeutics team consists of the world’s leading experts in resuscitation. Their data-driven approach to improving outcomes in CPR is precise and thoughtful, and from an engineering perspective is quite elegant. We are honored to collaborate with them in the development of the first innovative pneumatic cathlab vest-CPR device.”
CPR Therapeutics Inc.
CPR Therapeutics Inc. is a development stage medical device company developing the next-generation system for cardiopulmonary resuscitation.
Sudden cardiac arrest may be the single largest cause of death and years of lost life in Western countries. Improving outcomes for patients after cardiac arrest is one of the great unmet medical needs. Each year over 300,000 deaths occur following sudden cardiac arrest in the U.S. alone. Fifty years after the first description of modern cardiopulmonary resuscitation (CPR) survival is below 10%, and the standard-of-care for these patients remains manual chest compressions performed by people.
Studies have shown that precision sequencing and standardization of compressions can improve outcomes. Differences measured in milliseconds can alter outcomes. CPR Therapeutics Inc. is developing the first advanced technology automated CPR system that integrates and synchronizes multiple technological innovations into a single system that can be easily applied under emergency conditions. This advanced technology multimodal CPR cannot be performed by humans. It will enhance blood flow and the efficacy of electrical countershock in ways previously only available in laboratory settings. This system will, for the first time, demonstrate clinically significant improved survival. [email protected]tics.com